KDM4B Recombinant Monoclonal Antibody

Code: CSB-RA889767A0HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, IHC, IF, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

O94953

Target Names

KDM4B

Alternative Names

Lysine-specific demethylase 4B (EC 1.14.11.-) (JmjC domain-containing histone demethylation protein 3B) (Jumonji domain-containing protein 2B), KDM4B, JHDM3B JMJD2B KIAA0876

Species Reactivity

Human

Immunogen

A synthesized peptide from human KDM4B protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

1F9

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Immunohistochemistry (IHC) Protocol Immunofluorescence (IF) Protocol Flow Cytometry (FC) Protocol

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200
IF	1:50-1:200
FC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

IHC image of CSB-RA889767A0HU diluted at 1:100 and staining in paraffin-embedded human thyroid tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.
Immunofluorescence staining of U-251MG cell with CSB-RA889767A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
Overlay Peak curve showing PC-3 cells stained with CSB-RA889767A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

KDM4B, also known as JMJD2B, is a Jumonji domain-containing histone demethylase that specifically removes methyl groups from di- and tri-methylated lysine residues on histones H3K9 and H3K36. This enzymatic activity positions KDM4B as a critical regulator of chromatin accessibility and gene transcription, with established roles in cell cycle progression, DNA damage response, and hormone receptor signaling. Elevated KDM4B expression has been documented across multiple cancer types, making it a compelling target for researchers investigating epigenetic mechanisms in oncology and developmental biology.

This recombinant monoclonal antibody, generated in rabbit against a synthetic peptide derived from human KDM4B, offers the reproducibility and sequence-defined consistency that demanding epigenetic studies require. Unlike traditional hybridoma-derived antibodies, recombinant production ensures that each lot performs identically to the last, eliminating the variability that can compromise longitudinal studies or multi-site collaborations.

Validation across multiple detection platforms demonstrates this antibody's versatility in your experimental workflows. Immunohistochemistry staining in paraffin-embedded human thyroid tissue reveals clear nuclear localization patterns when used at dilutions between 1:50 and 1:200. Immunofluorescence studies in U-251MG glioblastoma cells confirm robust nuclear signal with minimal background, while flow cytometry analysis of PC-3 prostate cancer cells shows distinct positive population shifts compared to isotype controls.

The unconjugated format and affinity-purified preparation provide flexibility for pairing with your preferred secondary detection systems. Whether you are mapping KDM4B expression patterns in tumor specimens, investigating its recruitment dynamics at specific genomic loci, or screening for pathway modulators, this antibody delivers the specificity and consistency essential for advancing epigenetic research.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Histone demethylase that specifically demethylates 'Lys-9' of histone H3, thereby playing a role in histone code. Does not demethylate histone H3 'Lys-4', H3 'Lys-27', H3 'Lys-36' nor H4 'Lys-20'. Only able to demethylate trimethylated H3 'Lys-9', with a weaker activity than KDM4A, KDM4C and KDM4D. Demethylation of Lys residue generates formaldehyde and succinate.

Gene References into Functions

findings illustrate the significance of CREB-KDM4B-STAT3 signaling cascade in DNA damage response, and highlight that KDM4B may potentially be a novel oncotarget for colorectal cancer radiotherapy. PMID:29633065
p-ERK-mediated phosphorylation and stabilization of JMJD2B during glucose deprivation contributes to its role in glucose uptake and cell viability, which may be modulated through epigenetically upregulation of GLUT1 in colon cancer cells. PMID:28945223
KDM4B may play an important role in mitochondrial apoptosis and represent a potential therapeutic cancer target in colorectal cancer PMID:27506941
High KDM4B expression is associated with Neuroblastomas. PMID:28684529
This is the first demonstration that a Jumonji-domain histone demethylase regulates cellular processes required for peritoneal dissemination of cancer cells, one of the predominant factors affecting prognosis of EOC. The pathways regulated by KDM4B may present novel opportunities to develop combinatorial therapies to improve existing therapies for EOC patients. PMID:27869162
identification of JMJD2B/KDM4B as a p53-inducible gene in response to DNA damage. PMID:28073943
KDM4B and KDM4D expression may associate with an aggressive subtype of classical Hodgkin lymphoma and be linked with radioresistance PMID:27630312
KDM4B is a key mediator in epithelial-mesenchymal transition process, and may serve as an important prognostic marker and therapeutic target for the metastatic progression of human pancreatic cancer PMID:26511091
The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. CONCLUSION: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma PMID:27630338
upon TGF-beta stimulation, KDM4B was recruited to the SOX9 promoter, removed the silencing H3K9me3 marks, and activated the transcription of SOX9. PMID:26485430
High KDM4B expression is associated with endometrial cancer progression. PMID:26397136
JMJD2B and JMJD2C play an important role in the pathology of osteosarcoma via the up-regulation of FGF2. PMID:25636512
results reveal that JMJD2B is dramatically upregulated in hepatocellular carcinoma, making it a potential diagnostic marker for the further development of HCC treatment therapies PMID:25533242
Functional studies demonstrated that KDM4B regulates the Myc pathway. N-Myc was found to physically interact with and recruit KDM4B. KDM4B was found to regulate neuroblastoma cell proliferation and differentiation in vitro and xenograft growth in vivo. PMID:25925418
Data indicate that miR-491-5p plays a tumor suppressor role in the development and progression of breast cancer via direct targeting the 3'UTR of JMJD2B mRNA. PMID:25725194
Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer. PMID:24957706
KDM4B was upregulated in colon and rectal adenocarcinomas and required for efficient growth and clonogenic activity of human HT-29 colon cancer cells. PMID:24481461
A novel function of JMJD2B in promoting epithelial-mesenchymal transition and gastric cancer invasion and metastasis. PMID:24077348
Results suggest that by regulating JMJD2b and SUV39H1 expression, p53 not only controls transcription but also promotes HC relaxation to accelerate a rate-limiting step in the repair of complex genomes. PMID:23376847
Jumonji domain-containing protein 2B has an essential role in cancer cell survival and tumor growth via DNA damage response mediation, which STAT3 partially regulates. PMID:24473398
novel pathway by which Hsp90 activity alters the histone code via regulation of KDM4B stability. PMID:23589305
JMJD2B may play a central role in gastric cancer cell growth and might constitute a novel therapeutic target to overcome hypoxia-induced radio-resistance, thereby improving the efficiency of radiation therapy. PMID:23046878
JMJD2B interacts with ERalpha and components of the SWI/SNF-B chromatin remodeling complex. JMJD2B is recruited to ERalpha target sites, demethylates H3K9me3 and facilitates transcription of ER responsive genes including MYB, MYC and CCND1. PMID:21445275
The histone demethylases KDM4B and KDM6B play critical roles in osteogenic commitment of mesenchymal stem/stromal cells. PMID:22770241
showed that JMJD2B was overexpressed in colorectal cancer tissues and positively correlated with expression of the hypoxic marker carbonic anhydrase 9 PMID:22745382
High JMJD2B is associated with bladder and lung carcinogenesis through positive regulation of cyclin-dependent kinase 6. PMID:21930796
JMJD2B is required for sustained proliferation and survival of tumor cells in vitro and in vivo, and its aberrant expression may contribute to the pathogenesis of gastric cancer. PMID:22133676
knockdown of JMJD2B severely impairs estrogen-induced cell proliferation and the tumor formation capacity of breast cancer cells PMID:21445275
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. PMID:21502505
Histone demethylase JMJD2B is regulated by both ERalpha and HIF-1alpha, drives breast cancer cell proliferation in normoxia and hypoxia, and epigenetically regulates the expression of cell cycle genes. PMID:20682797
Two GATA-binding sites within intron 6 of human JMJD2B gene were conserved in mouse Jmjd2b gene. PMID:17611647
Results show that many genes regulated by hypoxia and HIF-1alpha show patterns of induction with JMJD (Jumonji-domain containing)1A and JMJD2B demonstrating robust, and JMJD2C more modest, up-regulation by hypoxia. PMID:18713068
histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF PMID:18984585